

## PRESS NEWS

### **Gisela Sitbon, Rolf Ehrnström and Simon Turner new board members of Gradientech**

*Uppsala, May 25, 2020.* Gradientech is pleased to announce the appointment of three new members to the company's board including a new board chair, effective from May 14, 2020. The new board members have been recruited to strengthen the company with internationally acquired key competences to prepare for the market launch of Gradientech's *in vitro* diagnostic system for ultra-rapid antibiotic susceptibility testing.

**Dr. Gisela Sitbon**, new chair of the board, has a research background within molecular biology, combined with more than 25 years of senior level experience from the life science industry. This includes business development and operational positions, as well as co-founding and managing a service-providing diagnostic company, later acquired by Capiro. Sitbon has held numerous board positions within pharmaceutical, diagnostics and venture capital fund companies. She currently holds several chair positions and board appointments in private and stock market listed companies. **Rolf Ehrnström** has extensive experience leading R&D at biotech and diagnostic companies like Amersham Pharmacia Biotech, Dako (acquired by Agilent) and the microfluidics pioneer company Gyros. Ehrnström is today CSO of the stock market listed diagnostics company Immunovia, and appointed independent partner at Ventac Partners.

**Simon Turner** has a background as an investment analyst, with focus on diagnostics, medtech and digital solutions. Turner has solid experience from international due diligence work at French Kurma Partners, and later as Senior Manager Innovation Scout at Baxter International.

"We are very happy to welcome our three new, highly experienced and competent board members. I am truly looking forward to working together to put Gradientech on the international map of leading diagnostic companies that provide solutions to global health issues," says CEO and Gradientech co-founder Sara Thorslund.

Gradientech has, in addition, recruited Hanna Gradin as new QA/Regulatory Affairs Manager, with solid experience from medical device and pharmaceutical companies like Galderma and Orexo. Gradin was most recently working as auditor for the accredited certification body Nordic Certification.

*Gradientech is a public company developing the *in vitro* diagnostic QuickMIC® system, a new platform based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reduce healthcare costs and lowering the spread of antibiotic resistance. [www.gradientech.se](http://www.gradientech.se)*

#### **For further information, please contact:**

Sara Thorslund, PhD, CEO Gradientech

Tel: +46 736 29 35 80, email: [sara.thorslund@gradientech.se](mailto:sara.thorslund@gradientech.se)